Leqembi included in China’s commercial insurance innovative drug list December 9, 2025 00:30 Non Regulatory Read more
New Leqembi-data presented at CTAD 2025 suggests potential to delay disease progression by up to 8.3 years with continued treatment December 4, 2025 07:45 Non Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of November 28, 2025 November 28, 2025 18:30 Regulatory Read more
New drug application for subcutaneous formulation of Leqembi[®] submitted in Japan November 28, 2025 06:30 Regulatory Read more
Eisai completes U.S. rolling sBLA submission for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose November 25, 2025 13:37 Regulatory Read more
New data on lecanemab to be presented at CTAD conference November 19, 2025 00:30 Non Regulatory Read more
Leqembi® approved for IV maintenance treatment in the United Kingdom November 14, 2025 00:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s third quarter report for July – September 2025 on November 13 at 9.30 a.m. CET November 4, 2025 10:00 Non Regulatory Read more
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025 October 30, 2025 11:00 Regulatory Read more
Health Canada Grants Authorization for Leqembi® (lecanemab) October 27, 2025 00:35 Non Regulatory Read more
First patient treated with Leqembi® (lecanemab) in the Nordics October 14, 2025 09:05 Non Regulatory Read more
Leqembi® Iqlik™ (lecanemab-irmb) selected by TIME as one of the best innovations of 2025 October 14, 2025 07:00 Non Regulatory Read more
Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S. October 6, 2025 22:35 Non Regulatory Read more
Leqembi® approved for IV maintenance treatment in China September 29, 2025 08:15 Regulatory Read more
Leqembi® approved for the treatment of early Alzheimer’s disease in Australia September 24, 2025 08:40 Regulatory Read more
Gunilla Osswald awarded Uppsala University Alumnus of the year 2025 September 9, 2025 09:05 Non Regulatory Read more
BioArctic’s founders intend to divest minor part of their shareholding September 3, 2025 17:35 Regulatory Read more
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as a subcutaneous starting dose for the treatment of early Alzheimer’s disease under Fast Track status September 3, 2025 01:30 Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of August 29, 2025 September 1, 2025 18:30 Regulatory Read more
US FDA approves Leqembi® IQLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease August 29, 2025 23:55 Regulatory Read more
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties August 26, 2025 07:05 Regulatory Read more
Invitation to presentation of BioArctic’s second quarter report for April – June 2025 on August 28 at 9.30 a.m. CET August 21, 2025 09:00 Non Regulatory Read more
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025 July 31, 2025 12:00 Regulatory Read more
Latest data presented at AAIC 2025 reinforces lecanemab’s clinical effect with consistent safety profile July 31, 2025 01:30 Non Regulatory Read more
Lecanemab four-year efficacy and safety data to be presented at AAIC 2025 July 22, 2025 08:00 Non Regulatory Read more
The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association July 16, 2025 09:30 Non Regulatory Read more
Professor Lars Lannfelt to receive the 2025 Hartwig Piepenbrock-DZNE Prize June 26, 2025 10:15 Non Regulatory Read more
BioArctic to initiate next cohorts in exidavnemab Phase 2a study after positive safety review June 13, 2025 08:00 Regulatory Read more
BioArctic’s Capital Markets Day 2025 – entering a new era of growth June 2, 2025 10:30 Non Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of May 30, 2025 May 30, 2025 18:30 Regulatory Read more
Bulletin from the Annual General Meeting in BioArctic AB (publ) May 22, 2025 18:18 Regulatory Read more
BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy May 22, 2025 15:15 Regulatory Read more
Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026) May 15, 2025 06:00 Regulatory Read more
Invitation to presentation of BioArctic’s first quarter report for January – March 2025 on May 21 at 9.30 a.m. CET May 13, 2025 08:30 Non Regulatory Read more
Exidavnemab phase 2a study expanded to include MSA patients May 8, 2025 13:30 Non Regulatory Read more
Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025 May 1, 2025 12:45 Regulatory Read more
MHRA to evaluate monthly intravenous maintenance dosing of Leqembi[®] for the treatment of early Alzheimer’s disease in the UK April 30, 2025 09:30 Non Regulatory Read more
BioArctic receives European substance patent for exidavnemab April 23, 2025 13:00 Non Regulatory Read more
Notice of Annual General Meeting 2025 in BioArctic AB (publ) April 22, 2025 20:00 Regulatory Read more
BioArctic publishes the Annual Report and Sustainability Report for 2024 April 22, 2025 20:00 Regulatory Read more
EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease (Extended information) April 16, 2025 01:10 Regulatory Read more
EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease April 15, 2025 17:25 Regulatory Read more
The European Commission to make final decision on EU Marketing Authorisation for lecanemab April 14, 2025 13:00 Regulatory Read more
Exidavnemab and lecanemab data presented at the 2025 AD/PD™ congress April 7, 2025 12:00 Regulatory Read more
The European Commission refers lecanemab decision to Appeal Committee April 1, 2025 12:00 Regulatory Read more
Invitation to BioArctic’s Capital Markets Day 2025 in Stockholm March 27, 2025 10:00 Non Regulatory Read more
Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress March 27, 2025 08:00 Non Regulatory Read more
BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference March 25, 2025 07:50 Regulatory Read more
BioArctic receives Orphan Drug Designation for exidavnemab the US March 17, 2025 18:25 Regulatory Read more
Lars Lannfelt, Pär Gellerfors, and Gunilla Osswald awarded Uppsala University’s Innovation and Entrepreneurship Prize March 12, 2025 08:00 Non Regulatory Read more
Therapeutic Goods Administration decides not to register lecanemab in Australia March 3, 2025 09:00 Non Regulatory Read more
Number of shares and votes in BioArctic AB (publ) as of February 28, 2025 February 28, 2025 18:30 Regulatory Read more
The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive opinion for Lecanemab in early Alzheimer’s disease in the EU February 28, 2025 14:00 Regulatory Read more
BioArctic’s global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing February 20, 2025 06:30 Regulatory Read more
Leqembi® sales reaches €200 million – first sales milestone achieved February 18, 2025 08:00 Regulatory Read more
Sales of Leqembi® totaled 13.3 billion yen in the fourth quarter 2024 February 7, 2025 04:35 Regulatory Read more
Invitation to presentation of BioArctic’s fourth quarter report for October – December 2024 February 5, 2025 08:30 Non Regulatory Read more
Update on regulatory review of lecanemab for treatment of early Alzheimer’s disease in the European Union January 31, 2025 12:30 Regulatory Read more
FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer’s Disease in the US January 27, 2025 00:30 Regulatory Read more
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US January 14, 2025 01:00 Non Regulatory Read more
